A Phase II/III Randomized, Double-Blind Study of Paclitaxel Plus Carboplatin in Combination With Vorinostat or Placebo in Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small-Cell Lung Cancer (NSCLC)

NCT00473889 Phase 2/Phase 3 TERMINATED Results posted

This Phase III clinical trial which incorporates an initial Phase II component will determine the survival of advanced Non-small cell lung cancer patients when treated with MK0683 and paclitaxel plus carboplatin

Details

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 2/Phase 3
Status	TERMINATED
Enrolment	253
Start date	2007-05
Completion	2008-12

Conditions

• Stage IIIB or IV Non-Small Cell Lung Cancer

Interventions

• vorinostat
• Comparator: paclitaxel
• Comparator: carboplatin
• Comparator: placebo

Primary outcomes

• Overall Survival — Start of treatment to death
  Defined as the time from date of randomization to death due to any cause. Patients without documented death at the time of the final analysis will be censored at the date of the last follow-up.